Review of diabetes medicines called SGLT2 inhibitors
The Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of canagliflozin, dapagliflozin and empagliflozin, which are medicines known as SGLT2 inhibitors used to treat type 2 diabetes. The aim of the review is to evaluate the risk of diabetic ketoacidosis with these medicines. Diabetic ketoacidosis is a serious condition that usually develops in people with type 1 diabetes when insulin levels are too low.
More information is included in the table below.
Agenda
Start of referral procedure
Related content
Related content
Related documents
Related documents
Contact point
Contact point